menu
    • menu
    [{"orgOrder":0,"company":"Vaximm AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"VXM01","moa":"VEGFR-2","graph1":"Oncology","graph2":"Phase I","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vaximm AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vaximm AG \/ Undisclosed"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"Merck Group | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"VXM01","moa":"VEGFR-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ Merck Group | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Vaximm AG \/ Merck Group | Pfizer Inc"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"VXM01","moa":"VEGFR-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Vaximm AG \/ Undisclosed"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"VXM01","moa":"VEGFR-2","graph1":"Oncology","graph2":"Phase I","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vaximm AG \/ Undisclosed"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"VXM01","moa":"||VEGFR-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaximm AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Vaximm AG \/ Merck Group"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"BCM Europe AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2025","type":"Licensing Agreement","leadProduct":"VXM01","moa":"VEGFR-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaximm AG","amount2":0.83999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.83999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ BCM Europe AG","highestDevelopmentStatusID":"7","companyTruncated":"Vaximm AG \/ BCM Europe AG"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"BCM Europe","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2025","type":"Licensing Agreement","leadProduct":"VXM01","moa":"VEGFR-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaximm AG","amount2":0.83999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.83999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Vaximm AG \/ BCM Europe","highestDevelopmentStatusID":"7","companyTruncated":"Vaximm AG \/ BCM Europe"}]

    Find Clinical Drug Pipeline Developments & Deals for VXM01

    Menu

    VXM01

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BCM Europe

                            Deal Size : $835.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Osr Holdings Nears Major Licensing Deal for Oral Cancer Immunotherapy

                            Details : Through the licensing deal for VXM01, a vaccine targeting VEGFR-2, the agreement aims to advance treatment options for glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : $20.0 million

                            December 01, 2025

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BCM Europe

                            Deal Size : $835.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BCM Europe AG

                            Deal Size : $835.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Vaximm AG Enters Term Sheet With BCM Europe for Potential VXM01 License

                            Details : Through the licensing deal for VXM01, a cancer vaccine targeting VEGFR-2, the agreement aims to advance cancer treatment.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : $20.0 million

                            November 21, 2025

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BCM Europe AG

                            Deal Size : $835.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXM01,Avelumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vaximm Shares VXM01-Avelumab Combo Results in Glioblastoma

                            Details : VXM01 is an investigational oral anti-VEGFR-2 vaccine, which is being evaluated in combination with avelumab (PD-L1 inhibitor) for treating patients with recurrent glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 26, 2025

                            Lead Product(s) : VXM01,Avelumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck Group | Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

                            Details : VXM01 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 21, 2018

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck Group | Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma

                            Details : VXM01 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 24, 2016

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis

                            Details : VXM01 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 24, 2016

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Vaximm AG

                            Switzerland arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Canc...

                            Details : VXM01 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 06, 2011

                            Lead Product(s) : VXM01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.